Volume 20, Number 1—January 2014
Research
Dynamic Modeling of Cost-effectiveness of Rotavirus Vaccination, Kazakhstan
Birgitte Freiesleben de Blasio
, Elmira Flem, Renat Latipov, Ajnagul Kuatbaeva, and Ivar Sønbø Kristiansen
, Elmira Flem, Renat Latipov, Ajnagul Kuatbaeva, and Ivar Sønbø Kristiansen
Table 1
Natural history and vaccine-related parameters used in dynamic modeling of cost-effectiveness of rotavirus vaccination, Kazakhstan
| Parameter | Base value [range] | Reference/source |
|---|---|---|
| Demographic | ||
| Population during 1980 | 15,926 million | (16) |
| Birth cohort* | [217,580–367,750] | (16,17) |
| Mortality rate in <1 y* | 20–54 per 1,000 births | (16,17) |
| Mortality rate in 1–4 y* | 3.9–6.3 per 1,000 births | (16,17) |
| Net yearly migration rate* | −18.6–0.1 per 1,000 | (16,17) |
| Deaths per year* |
[128,570–180,000] |
(16,17) |
| Natural history | ||
| Duration of maternal protection | 70 d | (18) |
| Duration of latency period | 0.5 d | (19) |
| Infectious period (days) | 8 (first); 6 (second); 4 (later) | (20–22) |
| Relative susceptibility | 1 (first); 0.62 (second); 0.40 (later) | (23) |
| Relative infectiousness | 1 (first); 0.5 (second); [0.1–0.2] (later) | Author assumption |
| Proportion of infections with RVGE | 0.47(first); 0.25 (second); 0.24 (later) | (23) |
| Severe RVGE | 0.13 (first); 0.04 (second); 0 (later) | (23) |
| Duration of complete immunity |
[6–12 mo] |
(24) |
| Vaccination | ||
| Sero-conversion rate | 0.96 | (25) |
| Relative infectiousness† Relative susceptibility† | 0.5 0.62 | Assumption Author assumption |
| Prop. of infections with RVGE | 0.30 [0.25–0.35] | (25–27) |
| Severe RVGE | 0.1175 [0.0885–0.139] | (25–27) |
| Coverage | 0.9 [0.8–1.0] | Author assumption |
| Duration of complete immunity |
12–24 mo] |
Author assumption |
| Fitted‡ | ||
| Infectivity parameter, β0 | 1.889–2.605 | Author calculation |
| Seasonal forcing, β1 | 0.025–0.046 | Author calculation |
| Phase angle, θ | 0.011–0.251 | Author calculation |
| Mixing (relative susceptibility)§
0–7m, 8–23 m, 24–35 m |
1.077–2.765 |
Author calculation |
| *Demographic parameters vary over the time period 1980-2031; only minimum and maximum values are listed in the table. All simulations are performed using the same set of demographic parameters. †Vaccine efficacy calculated for children with no previous natural infection. ‡Details on the fitted parameters of the five candidate models; see corresponding model fits in Technical Appendix Table; seasonal forcing: β0(1 + β1)sin(2πt / 365 + 0). §Relative susceptibility in children <3 years (Technical Appendix, section 1). | ||
Page created: January 03, 2014
Page updated: January 03, 2014
Page reviewed: January 03, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.